Investor News

Dear Investor,

There are always islands of opportunities in every difficulty!

2018 will provide TOPADUR with even more opportunties due to the fact that we are in transition from a pre-clinical to a clinical stage company and as a second major milestone will finalize the very important toxicology studies by the end of July 2018.

From your point of view our sector will most certainly provide new opportunities and an ideal occasion for an in depth market and investment reflection. We hope to draw your attention with regard to the current investment environment in general and particularly in the biotechnology sector in Switzerland.

So, why not considering an alternative investment in TOPADUR in the near future?

 

CURRENT TOPADUR BUSINESS PRESENTATION JULY 2018

 

BIOTECHNOLOGY INVESTMENTS IN SWITZERLAND

A short market review about the very interesting BIOTECHNOLOGY SECTOR in SWITZERLAND and the Investors Outlook for 2018 and above present you a dynamic development in our small local Swiss biotechnology scene, which most certainly will also further enhance TOPADUR’s offering to be a lucrative Investment option.

For more INFORMATION
CLICK HERE

 

WHY SHOULD YOU INVEST IN TOPADUR ?

What exactly are the key arguments to be raised to actually invest in TOPADUR and what makes us an added value provider and important asset for your private equity portfolio ?

Find out more
CLICK HERE

 

CONTACT

The interested investors will obtain more information via our Investors Relations Contact below:

TOPADUR PHARMA AG
Markus Ducrey
Finance | Strategy
Grabenstrasse 11A
8952 Schlieren
SWITZERLAND

T: 41 44 755 44 61
investors@topadur.com